IL172616A0 - Metabolite of quetiapine - Google Patents

Metabolite of quetiapine

Info

Publication number
IL172616A0
IL172616A0 IL172616A IL17261605A IL172616A0 IL 172616 A0 IL172616 A0 IL 172616A0 IL 172616 A IL172616 A IL 172616A IL 17261605 A IL17261605 A IL 17261605A IL 172616 A0 IL172616 A0 IL 172616A0
Authority
IL
Israel
Prior art keywords
quetiapine
metabolite
Prior art date
Application number
IL172616A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Goldstein Jeffrey
Grimm Scott W
Winter Helen R
Davis Patricia C
Suckow Raymond F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Goldstein Jeffrey, Grimm Scott W, Winter Helen R, Davis Patricia C, Suckow Raymond F filed Critical Astrazeneca Ab
Publication of IL172616A0 publication Critical patent/IL172616A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL172616A 2003-07-02 2005-12-15 Metabolite of quetiapine IL172616A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
IL172616A0 true IL172616A0 (en) 2006-04-10

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172616A IL172616A0 (en) 2003-07-02 2005-12-15 Metabolite of quetiapine

Country Status (20)

Country Link
US (1) US20050026900A1 (enExample)
EP (1) EP1644005B1 (enExample)
JP (1) JP2007516193A (enExample)
KR (1) KR20060082037A (enExample)
CN (1) CN1816339B (enExample)
AR (1) AR045004A1 (enExample)
AT (1) ATE477803T1 (enExample)
AU (1) AU2004253334A1 (enExample)
BR (1) BRPI0412127A (enExample)
CA (1) CA2531284A1 (enExample)
DE (1) DE602004028739D1 (enExample)
ES (1) ES2349091T3 (enExample)
IL (1) IL172616A0 (enExample)
IS (1) IS8283A (enExample)
MX (1) MXPA05013869A (enExample)
NO (1) NO20060556L (enExample)
RU (1) RU2005141060A (enExample)
TW (1) TW200509944A (enExample)
UY (1) UY28400A1 (enExample)
WO (1) WO2005002586A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080065A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
WO2006073360A1 (en) * 2005-01-07 2006-07-13 Astrazeneca Ab NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
EP1865962A2 (en) * 2005-04-04 2007-12-19 Arcadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
JP2009516708A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
US20100022510A1 (en) * 2005-11-18 2010-01-28 Astrazeneca Ab Crystalline Forms
CN101360725B (zh) * 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
EP1951694A4 (en) * 2005-11-18 2010-09-22 Astrazeneca Ab FORMS OF SALTS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010531292A (ja) * 2006-12-20 2010-09-24 アストラゼネカ・アクチエボラーグ 化合物及びその使用
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
EP2120563A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USES
CN101641101A (zh) * 2007-03-22 2010-02-03 阿斯利康(瑞典)有限公司 治疗心境障碍的方法
EP2987789A1 (en) 2009-12-31 2016-02-24 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
LT2544536T (lt) 2010-03-11 2019-02-25 Kempharm, Inc. Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5661184A (en) * 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.

Also Published As

Publication number Publication date
US20050026900A1 (en) 2005-02-03
DE602004028739D1 (de) 2010-09-30
EP1644005B1 (en) 2010-08-18
AU2004253334A1 (en) 2005-01-13
JP2007516193A (ja) 2007-06-21
CN1816339B (zh) 2010-12-15
RU2005141060A (ru) 2006-07-27
WO2005002586A8 (en) 2006-02-09
KR20060082037A (ko) 2006-07-14
UY28400A1 (es) 2005-01-31
WO2005002586A1 (en) 2005-01-13
IS8283A (is) 2006-02-01
BRPI0412127A (pt) 2006-08-15
ATE477803T1 (de) 2010-09-15
CN1816339A (zh) 2006-08-09
TW200509944A (en) 2005-03-16
NO20060556L (no) 2006-04-03
CA2531284A1 (en) 2005-01-13
AR045004A1 (es) 2005-10-12
ES2349091T3 (es) 2010-12-27
MXPA05013869A (es) 2006-02-28
EP1644005A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
IL172616A0 (en) Metabolite of quetiapine
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
AU157139S (en) Toilet
AU2003236991A8 (en) Representations of processes
AU156435S (en) A set of bottles
AU2003232986A8 (en) Dc-dc-converter
PT1606462E (pt) Unidade sanitária de inserção
IL174213A0 (en) A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline
PL360722A1 (en) Lavatory-bidet bowl
GB0402479D0 (en) Toilet
GB0610137D0 (en) Metabolite
GB0309120D0 (en) A set of parts
HK1087023A (en) Metabolite of quetiapine
IL171945A0 (en) Iodopyrazolyl carboxanilides
GB2403147B (en) Self massage aid
PL356853A1 (en) Application of bacteriphages
TW553243U (en) Structure of clotheshanger
GB0326554D0 (en) Serfer of a wall
AU157275S (en) A set of bowls
AU148850S (en) A set of towels
GB0319490D0 (en) Language aid
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
AU151991S (en) Towel
AU152362S (en) Towel
AU155283S (en) Towel